Clovis Oncology (CLVS) and Immunomedics (IMMU) announced their intent to enter into a clinical collaboration to investigate the combination of Clovis’ Rubraca, a poly polymerase inhibitor, and Immunomedics’ lead antibody-drug conjugate product candidate, sacituzumab govitecan, as a treatment of patients with metastatic triple-negative breast cancer and metastatic urothelial cancer. The planned phase 1/2 study will include an initial safety cohort followed by expansion cohorts in each of mTNBC and mUC. In preclinical studies, the combination of sacituzumab govitecan and rucaparib in TNBC cell lines in vitro resulted in synergistic growth inhibition regardless of BRCA1/2 status. In addition, the combination of sacituzumab govitecan and a PARPi also demonstrated significant antitumor effects above that observed with monotherapy in BRCA wild-type and mutant animal models of TNBC.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.